Clinical Trial Update: Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis [Phase 2]

View source ↗

Summary

Phase 2 trial investigating safety and efficacy of eculizumab in patients with refractory generalized myasthenia gravis was terminated; results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• Eculizumab (eculizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Myasthenia Gravis | Phase 2 | Status: TERMINATED | Results posted: 2016-12-12